Health Care • Biotechnology: Pharmaceutical Preparations
$0.71 ▼ -0.04
(-4.81%)
MKT CAP: $205.7M • VOL: 2.78M
52W L $1 52W H $2
AKBA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $236.2M | $160.2M | $194.6M |
| YoY Revenue Growth % | +47.5% | -17.7% | — |
| Gross Profit | $196.7M | $97.0M | — |
| Gross Margin % | 83.3% | 60.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $23.5M | -$50.5M | -$46.3M |
| Operating Margin % | 9.9% | -31.5% | -23.8% |
| Net Income (GAAP) | -$5.3M | -$69.4M | -$51.9M |
| EBITDA (Normalized) | $23.7M | -$50.4M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $68.0M | -$40.7M | -$23.4M |
| Capital Expenditures (CapEx) | $291.0K | $33.0K | — |
| Free Cash Flow (FCF) | $67.7M | -$40.7M | -$23.4M |
| FCF Margin % | 28.7% | -25.4% | -12.0% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $184.8M | $51.9M | — |
| Total Debt (Short + Long Term) | $48.3M | $38.7M | — |
| Total Stockholders' Equity | $32.6M | -$49.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AKBA.